{"title":"COVID-19疫情和IBD患者:一个挑战","authors":"M. Maher, Hazem M Rizk","doi":"10.17554/j.issn.2224-3992.2020.09.981","DOIUrl":null,"url":null,"abstract":"The COVID-19 pandemic, caused by coronavirus 2 (SARS-CoV-2), has developed as a intense challenge for healthcare systems allover the world. COVID-19 can be associated with gastrointestinal (GI) inflammation as SARS-CoV-2 enters cells via its receptor the angiotensin-converting enzyme 2, which is expressed on GI cells. There was a great demand to clarify the impact of COVID-19 on patients with inflammatory bowel disease (IBD), particularly those on immunosuppressive medications.","PeriodicalId":90217,"journal":{"name":"Journal of gastroenterology and hepatology research","volume":"9 1","pages":"3354-3356"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 Outbreak and IBD Patient: A Challenge\",\"authors\":\"M. Maher, Hazem M Rizk\",\"doi\":\"10.17554/j.issn.2224-3992.2020.09.981\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The COVID-19 pandemic, caused by coronavirus 2 (SARS-CoV-2), has developed as a intense challenge for healthcare systems allover the world. COVID-19 can be associated with gastrointestinal (GI) inflammation as SARS-CoV-2 enters cells via its receptor the angiotensin-converting enzyme 2, which is expressed on GI cells. There was a great demand to clarify the impact of COVID-19 on patients with inflammatory bowel disease (IBD), particularly those on immunosuppressive medications.\",\"PeriodicalId\":90217,\"journal\":{\"name\":\"Journal of gastroenterology and hepatology research\",\"volume\":\"9 1\",\"pages\":\"3354-3356\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of gastroenterology and hepatology research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17554/j.issn.2224-3992.2020.09.981\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gastroenterology and hepatology research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17554/j.issn.2224-3992.2020.09.981","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The COVID-19 pandemic, caused by coronavirus 2 (SARS-CoV-2), has developed as a intense challenge for healthcare systems allover the world. COVID-19 can be associated with gastrointestinal (GI) inflammation as SARS-CoV-2 enters cells via its receptor the angiotensin-converting enzyme 2, which is expressed on GI cells. There was a great demand to clarify the impact of COVID-19 on patients with inflammatory bowel disease (IBD), particularly those on immunosuppressive medications.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
